Status: Finalised
First registered on:
31/07/2015
Last updated on:
31/07/2015
1. Study identification
EU PAS Register NumberEUPAS10483
Official titleIncreasing ICS Dose vs Add-on Therapy in Children with Asthma
Study title acronymPaediatric Asthma Step-up
Study typeObservational study
Brief description of the studyA historical observational database study UK using primary care data to evaluate the comparative effectiveness of different paediatric asthma step-up options with respect to asthma control at 12 months, specifically ICS dose increase; addition of LABA to existing ICS (as either a separate inhaler or as part of a fixed dose combination) or the addition of LTRA to existing LABA therapy.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsRIRL
Department/Research group
Organisation/affiliationResearch in Real Life Ltd.
Details of (Primary) lead investigator
Title Professor
Last name Turner
First name Stephen
Is this study being carried out with the collaboration of a research network?
Yes
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed03/12/201203/12/2012
Start date of data collection07/01/201307/01/2013
Start date of data analysis
Date of interim report, if expected
Date of final study report15/07/201515/07/2015
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government body
Research councils
EU funding scheme
OtherRespiratory Effectiveness Group70
Research in Real Life Ltd30
5. Contact details for enquiries
Scientific Enquiries
Title Miss
Last name Chisholm
First name Alison
Address line 15 Woodview
Address line 2
Address line 3
CityArundel
Postcode
CountryUnited Kingdom
Phone number (incl. country code)441903883797
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Miss
Last name Chisholm
First name Alison
Address line 15
Address line 2
Address line 3
CityArundel
Postcode
CountryUnited Kingdom
Phone number (incl. country code)441903883797
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Substance class (ATC Code)H02 (CORTICOSTEROIDS FOR SYSTEMIC USE)
Substance class (ATC Code)R03DC (Leukotriene receptor antagonists)
Substance class (ATC Code)R03 (DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES)
7. Medical conditions to be studied
Medical condition(s)Yes
Asthma
8. Population under study
Age
Children (2 - 11 years)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects17000
Additional information
ICS increase: n=10,768
FDC: n=1408
+LABA: n=3798
+LTRA: n=1282
10. Source of data
Is this study being carried out with an established data source?No
Sources of data
Routine primary care electronic patient registry
11. Scope of the study
What is the scope of the study?
Effectiveness evaluation
Primary scope : Effectiveness evaluation
12. Main objective(s)
What is the main objective of the study?
The primary focus is to investigate the relationship between a step-up in asthma treatment (i.e. addition of a long-acting β-agonist (LABA), leukotriene receptor antagonist (LTRA) or increased ICS dose) in children aged 5-12 and the impact on asthma control over a 12 month period.
Are there primary outcomes?Yes
Exacerbation Rate (ATS/ERS Definition)
Where an exacerbation is defined as the occurrence of:
(i) Asthma-related1:
a. Hospital attendance / admissions OR
b. A&E attendance
(ii) Use of acute oral steroids2
Are there secondary outcomes?Yes
Database Asthma Control, defined as:the absence of the following during the one-year outcome period:
(i) Asthma-related: Hospital admission, A&E attendance, Out of hours attendance, Out-patient department attendance
(ii) GP consultations for lower respiratory tract infection
(iii) Prescriptions for acute courses
Additional secondary measures:
Hospitalisations;
Adherence;
SABA usage
13. Study design
What is the design of the study?
Cohort study
14. Follow-up of patients
Will patients be followed up?Yes
Please describe duration of follow up
12 months following index date, where the index date is defined as the date of treatment step up
15. Data analysis plan
Please provide a brief summary of the analysis method
Patients will be characterised over a 1-year baseline period. For outcome evaluation, patients will be matched on on key clinical and demographic features to minimise differences between treatment arms and to minimise the risk of confounders. Remaining differences will be adjusted for using suitable statistical modelling.
Both unmatched and matched results will be reported, as well as matched results adjusted and unadjusted for residual confounders.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
